Validation of an Artificial Intelligence-Based Prediction Model Using 5 External PET/CT Datasets of Diffuse Large B-Cell Lymphoma.

convolutional neural networks diffuse large B-cell lymphoma maximum-intensity projection prediction time to progression

Journal

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410

Informations de publication

Date de publication:
03 Oct 2024
Historique:
received: 06 06 2024
accepted: 09 09 2024
medline: 4 10 2024
pubmed: 4 10 2024
entrez: 3 10 2024
Statut: aheadofprint

Résumé

The aim of this study was to validate a previously developed deep learning model in 5 independent clinical trials. The predictive performance of this model was compared with the international prognostic index (IPI) and 2 models incorporating radiomic PET/CT features (clinical PET and PET models).

Identifiants

DOI: 10.2967/jnumed.124.268191 PMID: 39362767
pubmed: 39362767
pii: jnumed.124.268191
doi: 10.2967/jnumed.124.268191
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024 by the Society of Nuclear Medicine and Molecular Imaging.

Auteurs

Maria C Ferrández (MC)

Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; m.c.ferrandezferrandez@amsterdamumc.nl.
Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, The Netherlands.

Sandeep S V Golla (SSV)

Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, The Netherlands.

Jakoba J Eertink (JJ)

Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

Sanne E Wiegers (SE)

Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, The Netherlands.

Gerben J C Zwezerijnen (GJC)

Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, The Netherlands.

Martijn W Heymans (MW)

Department of Epidemiology and Data Science, Amsterdam Public Health Research Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

Pieternella J Lugtenburg (PJ)

Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Lars Kurch (L)

Clinic and Polyclinic for Nuclear Medicine, Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany.

Andreas Hüttmann (A)

Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Christine Hanoun (C)

Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Ulrich Dührsen (U)

Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Sally F Barrington (SF)

School of Biomedical Engineering and Imaging Sciences, King's College London and Guy's and St Thomas' PET Centre, King's Health Partners, King's College London, London, United Kingdom.

N George Mikhaeel (NG)

Department of Clinical Oncology, Guy's Cancer Centre and School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom.

Luca Ceriani (L)

Department of Nuclear Medicine and PET/CT Centre, Imaging Institute of Southern Switzerland-EOC, Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.
SAKK Swiss Group for Clinical Cancer Research, Bern, Switzerland.

Emanuele Zucca (E)

SAKK Swiss Group for Clinical Cancer Research, Bern, Switzerland.
Department of Oncology, Oncology Institute of Southern Switzerland-EOC, Faculty of Biomedical Sciences, Università della Svizzera Italiana, Bellinzona, Switzerland.
Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland; and.

Sándor Czibor (S)

Department of Nuclear Medicine, Medical Imaging Centre, Semmelweis University, Budapest, Hungary.

Tamás Györke (T)

Department of Nuclear Medicine, Medical Imaging Centre, Semmelweis University, Budapest, Hungary.

Martine E D Chamuleau (MED)

Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

Josée M Zijlstra (JM)

Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

Ronald Boellaard (R)

Classifications MeSH